vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and KFORCE INC (KFRC). Click either name above to swap in a different company.
KFORCE INC is the larger business by last-quarter revenue ($330.4M vs $168.4M, roughly 2.0× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 0.1%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -3.7%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Kforce Inc. is a professional staffing and solutions firm headquartered in the United States. It provides skilled professional placements and specialized workforce solutions primarily across technology, finance & accounting, and healthcare segments, serving a wide range of mid-sized to large enterprise clients nationwide.
ESPR vs KFRC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $330.4M |
| Net Profit | — | $7.9M |
| Gross Margin | — | 27.3% |
| Operating Margin | 50.6% | 3.6% |
| Net Margin | — | 2.4% |
| Revenue YoY | 143.7% | 0.1% |
| Net Profit YoY | — | -2.7% |
| EPS (diluted) | $0.32 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $330.4M | ||
| Q4 25 | $168.4M | $332.0M | ||
| Q3 25 | $87.3M | $332.6M | ||
| Q2 25 | $82.4M | $334.3M | ||
| Q1 25 | $65.0M | $330.0M | ||
| Q4 24 | $69.1M | $343.8M | ||
| Q3 24 | $51.6M | $353.3M | ||
| Q2 24 | $73.8M | $356.3M |
| Q1 26 | — | $7.9M | ||
| Q4 25 | — | $5.2M | ||
| Q3 25 | $-31.3M | $11.1M | ||
| Q2 25 | $-12.7M | $10.4M | ||
| Q1 25 | $-40.5M | $8.1M | ||
| Q4 24 | — | $11.1M | ||
| Q3 24 | $-29.5M | $14.2M | ||
| Q2 24 | $-61.9M | $14.2M |
| Q1 26 | — | 27.3% | ||
| Q4 25 | — | 27.2% | ||
| Q3 25 | — | 27.7% | ||
| Q2 25 | — | 27.1% | ||
| Q1 25 | — | 26.7% | ||
| Q4 24 | — | 27.0% | ||
| Q3 24 | — | 27.9% | ||
| Q2 24 | — | 27.8% |
| Q1 26 | — | 3.6% | ||
| Q4 25 | 50.6% | 2.6% | ||
| Q3 25 | -11.4% | 4.5% | ||
| Q2 25 | 8.6% | 4.5% | ||
| Q1 25 | -34.0% | 3.5% | ||
| Q4 24 | -6.4% | 4.5% | ||
| Q3 24 | -31.0% | 5.3% | ||
| Q2 24 | 3.5% | 5.5% |
| Q1 26 | — | 2.4% | ||
| Q4 25 | — | 1.6% | ||
| Q3 25 | -35.9% | 3.3% | ||
| Q2 25 | -15.4% | 3.1% | ||
| Q1 25 | -62.2% | 2.5% | ||
| Q4 24 | — | 3.2% | ||
| Q3 24 | -57.2% | 4.0% | ||
| Q2 24 | -83.9% | 4.0% |
| Q1 26 | — | $0.46 | ||
| Q4 25 | $0.32 | $0.29 | ||
| Q3 25 | $-0.16 | $0.63 | ||
| Q2 25 | $-0.06 | $0.59 | ||
| Q1 25 | $-0.21 | $0.45 | ||
| Q4 24 | $-0.14 | $0.60 | ||
| Q3 24 | $-0.15 | $0.75 | ||
| Q2 24 | $-0.33 | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $1.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $117.4M |
| Total Assets | $465.9M | $384.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.3M | ||
| Q4 25 | $167.9M | $2.1M | ||
| Q3 25 | $92.4M | $1.3M | ||
| Q2 25 | $86.1M | $2.5M | ||
| Q1 25 | $114.6M | $444.0K | ||
| Q4 24 | $144.8M | $349.0K | ||
| Q3 24 | $144.7M | $127.0K | ||
| Q2 24 | $189.3M | $110.0K |
| Q1 26 | — | $117.4M | ||
| Q4 25 | $-302.0M | $124.6M | ||
| Q3 25 | $-451.4M | $132.1M | ||
| Q2 25 | $-433.5M | $134.4M | ||
| Q1 25 | $-426.2M | $138.0M | ||
| Q4 24 | $-388.7M | $154.6M | ||
| Q3 24 | $-370.2M | $167.4M | ||
| Q2 24 | $-344.2M | $166.6M |
| Q1 26 | — | $384.8M | ||
| Q4 25 | $465.9M | $365.6M | ||
| Q3 25 | $364.0M | $374.2M | ||
| Q2 25 | $347.1M | $373.6M | ||
| Q1 25 | $324.0M | $368.2M | ||
| Q4 24 | $343.8M | $357.8M | ||
| Q3 24 | $314.1M | $369.9M | ||
| Q2 24 | $352.3M | $362.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | — |
| Free Cash FlowOCF − Capex | — | $-7.4M |
| FCF MarginFCF / Revenue | — | -2.2% |
| Capex IntensityCapex / Revenue | 0.0% | 1.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $43.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $45.2M | $19.7M | ||
| Q3 25 | $-4.3M | $23.3M | ||
| Q2 25 | $-31.4M | $18.4M | ||
| Q1 25 | $-22.6M | $249.0K | ||
| Q4 24 | $-35.0M | $21.8M | ||
| Q3 24 | $-35.3M | $31.0M | ||
| Q2 24 | $-7.2M | $20.9M |
| Q1 26 | — | $-7.4M | ||
| Q4 25 | — | $16.7M | ||
| Q3 25 | — | $19.8M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $-3.9M | ||
| Q4 24 | — | $20.9M | ||
| Q3 24 | $-35.5M | $27.5M | ||
| Q2 24 | $-7.3M | $17.8M |
| Q1 26 | — | -2.2% | ||
| Q4 25 | — | 5.0% | ||
| Q3 25 | — | 6.0% | ||
| Q2 25 | — | 4.3% | ||
| Q1 25 | — | -1.2% | ||
| Q4 24 | — | 6.1% | ||
| Q3 24 | -68.7% | 7.8% | ||
| Q2 24 | -9.9% | 5.0% |
| Q1 26 | — | 1.0% | ||
| Q4 25 | 0.0% | 0.9% | ||
| Q3 25 | 0.0% | 1.1% | ||
| Q2 25 | 0.0% | 1.2% | ||
| Q1 25 | 0.0% | 1.3% | ||
| Q4 24 | 0.0% | 0.3% | ||
| Q3 24 | 0.3% | 1.0% | ||
| Q2 24 | 0.1% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.82× | ||
| Q3 25 | — | 2.11× | ||
| Q2 25 | — | 1.76× | ||
| Q1 25 | — | 0.03× | ||
| Q4 24 | — | 1.97× | ||
| Q3 24 | — | 2.18× | ||
| Q2 24 | — | 1.48× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
KFRC
Segment breakdown not available.
